Sino Biopharmaceutical has co-led the series D round together with Loyal Valley Capital, while K. Wah Group also contributed.
China-based antibody drug developer Akeso Biopharma collected $150m in a series D round on Saturday co-led by pharmaceutical firm Sino Biopharmaceutical and private equity firm Loyal Valley Capital.
Conglomerate K. Wah Group also took part in the round, as did Shenzhen Capital Group, Lake Bleu Capital, China Reform Conson Soochow Overseas Fund I, OrbiMed Healthcare Fund Management and CCB Capital, the investment arm of financial services firm China Construction Bank.
The round additionally featured a range of undisclosed investors.
Founded…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
